Atacicept in multiple sclerosis (ATAMS): A randomised, placebo-controlled, double-blind, phase 2 trial

The Lancet Neurology

Volumn 13, Issue 4, 2014, Pages 353-363

  Kappos, Ludwig ^a   Hartung, Hans Peter ^b   Freedman, Mark S ^c   Boyko, Alexey ^d   Radü, Ernst Wilhelm ^a   Mikol, Daniel D ^e   Lamarine, Marc ^f   Hyvert, Yann ^g   Freudensprung, Ulrich ^h   Plitz, Thomas ⁱ   van Beek, Johan ^j  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b Department of Orthopedic Surgery   (Germany)

^c OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^d PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY   (Russian Federation)

^e BIOGEN   (United States)

^f Quartz Bio   (Switzerland)

^g EMD Serono   (United States)

^h Stamford Consultants AG   (Switzerland)

ⁱ Shire AG   (Switzerland)

^j Biogen Idec International GmbH   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ATACICEPT; IMMUNOGLOBULIN; PLACEBO;

ADULT; ANTIBODY PRODUCTION; ARTICLE; AUSTRALIA; B LYMPHOCYTE; CANADA; CLINICAL PROTOCOL; CONTROLLED STUDY; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EUROPE; FEMALE; FOLLOW UP; GEOGRAPHIC DISTRIBUTION; HUMAN; HUMORAL IMMUNITY; IMMUNOMODULATION; INJECTION SITE REACTION; INTENTION TO TREAT ANALYSIS; INTERACTIVE VOICE RESPONSE SYSTEM; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; UNITED STATES;

ADULT; BRAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84896070550     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(14)70028-6     Document Type: Article

References (33)

1. Bar-Or A, Calabresi PA, Arnold D, et al. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol 2008, 63:395-400.
2. Hawker K, O'Connor P, Freedman MS, et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 2009, 66:460-471.
3. Kappos L, Li D, Calabresi PA, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet 2011, 378:1779-1787.
4. Naismith RT, Piccio L, Lyons JA, et al. Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial. Neurology 2010, 74:1860-1867.
5. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008, 358:676-688.
6. Marsters SA, Yan M, Pitti RM, Haas PE, Dixit VM, Ashkenazi A Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI. Curr Biol 2000, 10:785-788.
7. Seyler TM, Park YW, Takemura S, et al. BLyS and APRIL in rheumatoid arthritis. J Clin Invest 2005, 115:3083-3092.
8. Munafo A, Priestley A, Nestorov I, Visich J, Rogge M Safety, pharmacokinetics and pharmacodynamics of atacicept in healthy volunteers. Eur J Clin Pharmacol 2007, 63:647-656.
9. Tak PP, Thurlings RM, Rossier C, et al. Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study. Arthritis Rheum 2008, 58:61-72.
10. Dall'Era M, Chakravarty E, Wallace D, et al. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum 2007, 56:4142-4150.
11. Thangarajh M, Gomes A, Masterman T, Hillert J, Hjelmstrom P Expression of B-cell-activating factor of the TNF family (BAFF) and its receptors in multiple sclerosis. J Neuroimmunol 2004, 152:183-190.
12. Thangarajh M, Masterman T, Rot U, et al. Increased levels of APRIL (a proliferation-inducing ligand) mRNA in multiple sclerosis. J Neuroimmunol 2005, 167:210-214.
13. Thangarajh M, Kisiswa L, Pirskanen R, Hillert J The expression of BAFF-binding receptors is not altered in multiple sclerosis or myasthenia gravis. Scand J Immunol 2007, 65:461-466.
14. Carbonatto M, Yu P, Bertolino M, et al. Nonclinical safety, pharmacokinetics, and pharmacodynamics of atacicept. Toxicol Sci 2008, 105:200-210.
15. Gross JA, Dillon SR, Mudri S, et al. TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease impaired B cell maturation in mice lacking BLyS. Immunity 2001, 15:289-302.
16. Krumbholz M, Derfuss T, Hohlfeld R, Meinl E B cells and antibodies in multiple sclerosis pathogenesis and therapy. Nat Rev Neurol 2012, 8:613-623.
17. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005, 58:840-846.
18. (accessed Dec 2, 2013). http://neurostatus.net/index.php.
19. Wang L, Keen KJ, Holland B Estimation of reliability in a three-factor model. Stat Med 2011, 30:1254-1265.
20. Nicholas R, Straube S, Schmidli H, Schneider S, Friede T Trends in annualized relapse rates in relapsing-remitting multiple sclerosis and consequences for clinical trial design. Mult Scler 2011, 17:1211-1217.
21. Keene ON, Calverley PM, Jones PW, Vestbo J, Anderson JA Statistical analysis of exacerbation rates in COPD: TRISTAN and ISOLDE revisited. Eur Respir J 2008, 32:17-24.
22. Genovese MC, Kinnman N, de La Bourdonnaye G, Pena Rossi C, Tak PP Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: results of a phase II, randomized, placebo-controlled, dose-finding trial. Arthritis Rheum 2011, 63:1793-1803.
23. van Vollenhoven RF, Kinnman N, Vincent E, Wax S, Bathon J Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase II, randomized, placebo-controlled trial. Arthritis Rheum 2011, 63:1782-1792.
24. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 1999, 53:457-465. The Lenercept Multiple Sclerosis Study Group, The University of British Columbia MS/MRI Analysis GroupThe University of British Columbia MS/MRI Analysis Group.
25. van Oosten BW, Barkhof F, Truyen L, et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 1996, 47:1531-1534.
26. Kinnunen T, Chamberlain N, Morbach H, et al. Specific peripheral B cell tolerance defects in patients with multiple sclerosis. J Clin Invest 2013, 123:2737-2741.
27. Krumbholz M, Faber H, Steinmeyer F, et al. Interferon-β increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity. Brain 2008, 131:1455-1463.
28. Yang M, Sun L, Wang S, et al. Novel function of B cell-activating factor in the induction of IL-10-producing regulatory B cells. J Immunol 2010, 184:3321-3325.
29. Kato A, Truong-Tran AQ, Scott AL, Matsumoto K, Schleimer RP Airway epithelial cells produce B cell-activating factor of TNF family by an IFN-β-dependent mechanism. J Immunol 2006, 177:7164-7172.
30. Morel J, Roubille C, Planelles L, et al. Serum levels of tumour necrosis factor family members a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BLyS) are inversely correlated in systemic lupus erythematosus. Ann Rheum Dis 2009, 68:997-1002.
31. Arnason B Tumour necrosis factor neutralization in MS: a cautionary tale. Int MS J 2011, 17:63-68.
32. Sormani MP, Bruzzi P MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials. Lancet Neurol 2013, 12:669-676.
33. Katz D, Taubenberger JK, Cannella B, McFarlin DE, Raine CS, McFarland HF Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis. Ann Neurol 1993, 34:661-669.